Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01338870 · ClinicalTrials.gov registry record · Phase 2
Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 301
- Enrollment target
NCT01338870: Completed Phase 2 study, sponsored by Pfizer.
NCT01338870 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 301 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01338870, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 301 participants
- Enrollment target
Study Summary
B2611003 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 6 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.
Primary Outcome
HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. The normal range for the HbA1c test is between 4 percent (%) and 5.6%. HbA1c levels between 5.7% and 6.4% indicate increased risk of diabetes and levels of 6.5% or higher indicate diabetes.
Interventions
- DRUG Placebo
- DRUG 150 mg PF-04991532
- DRUG 25 mg PF-04991532
- DRUG 75 mg PF-04991532
- DRUG 300 mg PF-04991532
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
What the finished NCT01338870 record still lists
NCT01338870 is an interventional study that assigns participants to a tested intervention. The registered 301 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01338870 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01338870 about?
NCT01338870 is a clinical study titled "Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes". B2611003 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 6 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be pl...
What is the current status of trial NCT01338870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 301 participants. The study started on 2011-06. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01338870?
The interventions under investigation include: Placebo (DRUG), 150 mg PF-04991532 (DRUG), 25 mg PF-04991532 (DRUG), 75 mg PF-04991532 (DRUG), 300 mg PF-04991532 (DRUG).
Who is sponsoring clinical trial NCT01338870?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01338870's enrollment target sits among peer trials
301 167th of 2000 higher than 1,834 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005975 · 301 participants · Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia